Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JV-394 |
| Synonyms | |
| Therapy Description |
JV-394 are autologous T-cells that express a chimeric antigen receptor (CAR) against CD94, which potentially induce cytotoxicity against T/NK-cell tumors (Blood 146 (Supplement 1): 2337). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JV-394 | JV 394|JV394|Anti-CD94 CAR T cells | JV-394 are autologous T-cells that express a chimeric antigen receptor (CAR) against CD94, which potentially induce cytotoxicity against T/NK-cell tumors (Blood 146 (Supplement 1): 2337). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07382817 | Phase I | JV-394 | Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms | Recruiting | USA | 0 |